Qualigen Therapeutics, Inc. (NASDAQ:QLGN – Get Free Report) shares traded up 3.9% during trading on Tuesday . The company traded as high as $0.9199 and last traded at $0.8135. Approximately 616,500 shares changed hands during trading, a decline of 59% from the average daily volume of 1,521,488 shares. The stock had previously closed at $0.7828.
Qualigen Therapeutics Stock Performance
The stock has a market cap of $1.31 million, a PE ratio of -0.10 and a beta of 0.24. The business has a 50-day moving average of $0.92 and a 200 day moving average of $1.16.
About Qualigen Therapeutics
Qualigen Therapeutics, Inc (NASDAQ: QLGN) is a life sciences company headquartered in Westminster, Colorado, that combines immunodiagnostic reagents with novel immuno-oncology therapies. Operating through two primary business units—Qualigen Diagnostic Solutions and Qualigen BioTherapeutics—the company seeks to leverage its expertise in antibody engineering and assay development to address both clinical laboratory needs and unmet medical needs in oncology.
Through its Qualigen Diagnostic Solutions division, the company designs, manufactures and distributes immunoassay reagents, kits and related consumables for use in clinical and research laboratories.
Further Reading
- Five stocks we like better than Qualigen Therapeutics
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
